Longevity-Conference

Total Page:16

File Type:pdf, Size:1020Kb

Longevity-Conference Top-30 Longevity Conferences 2019-2020 Table of Contents Introduction 3 Infographic Mind Map 4 List of Top-30 Longevity Conferences in 2019 - 2020 5 Top-30 Longevity Conferences 2019-2020: Distribution by Country 7 Top-30 Longevity Conferences 2019-2020: Distribution by Region 8 Top-30 Longevity Conferences 2019-2020: Distribution by Main Topic 9 Top-30 Longevity Conferences 2019-2020: Fees 10 Top-30 Longevity Conferences 2019-2020: Location 11 Influential Past Conferences That Have Established Longevity as a Prominent Mainstream Topic 17 150 Longevity Conferences 2019-2020 24 Appendix I. Top-30 Longevity Conferences 2019-2020 Profiles 28 Disclaimer 60 Introduction 3 With the rapid development of the Longevity industry, the number of events dedicated to this topic has increased proportionately. These events differ in a number of ways including target audience, central topics being covered, entrance fee range, location, venue, etc. Potential participants need to be aware of such conferences details while planning which conferences to attend. This report aims to serve as a guide in this type of decision making, which also includes a cost-benefit analysis of the conferences themselves. The report presents the Top-30 conferences related to Longevity, providing key facts and figures on each. The Top-30 conferences chosen for this list, from 150 Longevity-themed conferences in total, satisfy the following criteria: ● They are well attended, with a large number of speakers as well as participants ● They include at least one panel on the topic of Longevity ● They feature speakers who are professionals in the industry As a number of conferences for 2020 have not yet been announced, we expect to be updating the report regularly, increasing both the number of the conferences covered and the quantity of information on them. Furthermore, the conferences on Longevity play a significant role in the development of the industry despite not being regular in some cases. Since the turn of the century, a number of conferences have proven to have a seminal role, often acting as centres of gravity for the industry or any of its constituent technologies. In many cases however their full significance does not become apparent without the benefit of hindsight. It is for these reasons that the report contains a section on the influential past conferences (with an emphasis on the rapid succession of Longevity conferences hosted by prominent financial institutions and media brands in the past few years) that helped to solidify Longevity as the prominent, mainstream topic that it is today. Top-30 Longevity Conferences 2019-2020: Regional Distribution United States Asia Europe UK Future of Aging and Gerontology Canada Top-30 Longevity Conferences 2019-2020: Country 5 Distribution 11 USA United 7 Kingdom 3 Canada The 2 Netherlands 1 Switzerland 1 Germany 1 Spain Czech 1 Republic 1 China 1 Japan This chart illustrates the country distribution of Longevity conferences. While the USA is the 1 Singapore country with the largest proportion of conferences, Europe is home to the largest fraction of conferences in total, with only 3 of the Top-30 Longevity conferences being located in Asia. Top-30 Longevity Conferences 2019-2020: Regional Distribution 6 This chart illustrates the regional distribution of the Longevity conferences. The largest proportion of Longevity conferences in 2019-2020 are held in the US. This confirms that the industry is developing rapidly in the country. However, it is important to note that other regions and countries, namely Europe, UK and Canada have the substantial share of the conferences, and that the proportion of conferences held in these regions appears to be growing. On the other hand, although Asia does not contain a large fraction of the conferences yet, the proportion is likely to increase in the coming years due to the large volume of Longevity-industry dealflow coming out of Asia-based Longevity investors. Top-30 Longevity Conferences 2019-2020: Distribution by Main 7 Topic Although Longevity, aging and gerontology have similar and often-synonymized meanings, the characteristics of the conferences dedicated to each of this topics differ. While solely gerontology conferences are usually created for quite narrow circles of scientists, the conferences on aging as a whole are attracting a generally wider audience. The conferences that are held under the label of “Longevity” typically aim to attract the most influential people in the Longevity segment, with a higher degree of emphasis on Longevity investors, companies and entrepreneurs, and also typically have much greater entrance costs. Top-30 Longevity Conferences 2019-2020: Fees 8 $0-$500 $500+ Top-30 Longevity Conferences Locations 9 British Society of Gerontology Conference britishgerontology.org Ending Age-Related Diseases leafscience.org 10 - 12 July 2019 Location: UK Price: £595 11-12 July 2019 Location: US Price: $532 Speakers: TBD (already in the list: Bangor University, Wales; Frankfurt Forum for interdisciplinary Ageing Research) 34 speakers (e.g. Harvard Medical School, The Buck Institute for Research on Aging, Yale Center for Research on Aging, etc) Attending: Health Professionals, Pharma Corporations, Academia Attending: Health Professionals, Pharma Corporations, Academia, AI Companies Ageing, Health & Rejuvenation nature.com 23 - 26 June 2019 Location: The Netherlands Price: $850 Speakers: 26 (e.g. Buck Institute, Harvard University, Albert Einstein College of Medicine, etc) Attending: Health Professionals, Academia Longevity Therapeutics longevity-therapeutics.com Longevity Summit events.economist.com 29 - 31 January 2019 Location: US Price: $2598 27 September 2018 Location: Singapore Price: S$360 23 speakers (e.g. Insilico Medicine, Longeveron LLC, SENS Foundation, University of Liverpool, etc) 25 speakers (e.g. Amgen, Holmusk, Women’s Initiative for Ageing Successfully, Renaissance, etc.) Attending: Health Professionals, Pharma and Tech Corporations, Academia Attending: Financial Industry and Government Representatives, Policy Makers, Academia Top-30 Longevity Conferences Locations 10 ICAA Conference, Leadership Summit and Expo 2019 Global Ageing Conference icaa.cc thisisltc2019.com 10 - 12 October 2019 Location: US Price: $589 17 - 19 September 2019 Location: Canada Price: $999 100 speakers (e.g. American Senior Communities, Airbnb, Karolinska 150+ speakers (e.g. Baycrest Health Sciences, University of Manitoba, Institute, and others) Canadian Institute for Health Information, etc.) Attending: Senior Management, Pharma and Tech Corporations, Attending: Health Professionals, Academia, AI Companies Academia Future of Aging and Gerontology lexisconferences.com 02 - 03 August 2019 Location: US Price: $599 RAADFest raadfest.com 30 speakers Attending: Health Professionals, Pharma and Tech Corporations, 03 - 06 October 2019 Location: US Price: $883 Academia 25 speakers (e.g. BioViva, Chaga Inc, SENS Foundation, etc) Attending: Policy Makers, Pharma and Tech Corporations, Academia Aging, Drug Discovery & Artificial Intelligence basellife.org 10 - 12 September 2019 Location: Switzerland Price: N/A 23 speakers (e.g. University of California, University of Washington, SENS Research Foundation, etc) Attending: Health Professionals, Academia, Pharma and Tech Corporations Top-30 Longevity Conferences Locations 11 AGE-WELL 2019 Anti Aging Conference London agewell-nce.ca antiageingconference.com 22 - 24 October 2019 Location: Canada Price: $375 11 - 12 October 2019 Location: UK Price: £200 Speakers: TBD (already in the list: Canadian Space Agency) Speakers: TBD (already in the list: International Observatory of Attending: Pharma and Tech Corporations, Academia, Health Oxidative Stress, Institut Européen de la Longévité, Chulalongkorn Professionals University School of Sports Science) Attending: Health Professionals, Pharma Corporations, Academia Master Investor Masterclass: Investing in the age of longevity eventbrite.co.uk 13 November 2019 Location: UK Price: £300 Speakers: TBD Attending: Financial Industry Exponential Medicine Targeting Metabesity exponential.singularityu.org metabesity2019.com 04 - 07 November 2019 Location: US Price: $4,250 15 - 16 October 2019 Location: US Price: N/A Speakers: TBD 16 speakers (e.g. Buck Institute for Research on Aging, Aisling Capital, FDA CDER, etc) Attending: Health Professionals, Pharma and Tech Corporations, Academia Attending: Health Professionals, Policy Makers, Academia Top-30 Longevity Conferences Locations 12 GSA 2019 Annual Scientific Meeting geron.org Future of Ageing 2019 futureofageing.org.uk 13 - 17 November 2019 Location: US Price: $865 5 December 2019 Location: UK Price: £359 50+ speakers (e.g. University of Connecticut, University of Indianapolis, University of Nebraska at Omaha) Speakers: TBD (12 speakers already in the list, including London Business School, University of Kent, Open University) Attending: Health Professionals, Pharma Corporations, Academia Attending: Health Professionals, Pharma and Tech Corporations, Academia, Financial Industry and Government Representatives, Policy Makers 2nd Annual Longevity Forum thelongevityforum.com 14 November 2019 Location: UK Price: N/A Speakers: TBD Attending: Health Professionals, Academia, Pharma and Tech Corporations Aging in America Conference asaging.org Longevity World Forum 24 - 27 March 2020 Location: US Price: $960 longevityworldforum.com Speakers: TBD 14 - 15 November 2019 Location: Spain Price: €250 Attending: Health Professionals, Pharma and Tech Corporations, 9 speakers
Recommended publications
  • SENS-Research-Foundation-2019
    by the year 2050, cardiovascular an estimated 25-30 the american 85 percent of adults disease years and older age 85 or older remains the most population will suffer from common cause of 2 1 2 dementia. death in older adults. triple. THE CLOCK IS TICKING. By 2030, annual direct The estimated cost of medical costs associated dementia worldwide was 62% of Americans with cardiovascular $818 billion diseases in the united over age 65 have in 2015 and is states are expected to more than one expected to grow to rise to more than chronic condition.1 3 $2 trillion $818 billion. by 2030.1 References: (1) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5732407/, (2) https://www.who.int/ageing/publications/global_health.pdf, (3) https://www.cdcfoundation.org/pr/2015/heart-disease-and-stroke-cost-america-nearly-1-billion-day-medical-costs-lost-productivity sens research foundation board of directors Barbara Logan Kevin Perrott Bill Liao Chairperson Treasurer Secretary Michael Boocher Kevin Dewalt James O’Neill Jonathan Cain Michael Kope Frank Schuler 02 CONTENTS 2019 Annual Report 04 Letter From The CEO 06 Outreach & Fundraising 08 Finances 09 Donors erin ashford photography 14 Education 26 Investments 20 Conferences & Events 30 Research Advisory Board 23 Speaking Engagements 31 10 Years Of Research 24 Alliance 32 MitoSENS 34 LysoSENS 35 Extramural Research 38 Publications 39 Ways to Donate cover Photo (c) Mikhail Leonov - stock.adobe.com special 10th anniversary edition 03 FROM THE CEO It’s early 2009, and it’s very late at night. Aubrey, Jeff, Sarah, Kevin, and Mike are sitting around a large table covered in papers and half-empty food containers.
    [Show full text]
  • 5 EVENTS in ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland
    FIFTH ANNUAL - LIFE SCIENCE R&D DATA INTELLIGENCE LEADERS FORUM Basel, Switzerland January 23-24th, 2018 Optional Workshop 22nd, January Hear keynote presentations from the experts: Etzard Stolte Global Head Knowledge Management Roche, Switzerland Abhimanyu Verma 5 EVENTS IN ONE: Head Real World Evidence and Big Data Solutions Novartis, Switzerland Day 1: Torsten Niederdraenk Head of Technology Center Strategic Developments in R&D Big Siemens Healthcare, Germany Data Catherine Brownstein Scientific Director Day 2 (am): Stream 1 Manton Center for Orphan Disease Research Boston Children’s Hospital, USA Discovery & Omics Data Excellence Navin Ramachandran Radiology Consultant Day 2 (am): Stream 2 University College London Hospitals NHS Foundation Trust, Healthcare specialist in distributed ledgers and IoT Clinical & Patient Level Data IOTA Foundation, UK Excellence Marie-Claire Peakman Executive Director, Head Hit Discovery & Lead Profiling, Medicine Design Day 2 (pm): Stream A Pfizer, USA R&D IT & Bioinformatics Alex Zhavoronkov Co-founder, Insilico Medicine, CSO Day 2 (pm): Stream B The Biogerontology Research Foundation, UK Ivana Schnur Digital Health Collaborations Co-founder, CMO Sense.ly, USA Pre-Event Workshop: Jan 22nd Paul Wicks Artificial Intelligence for Drug Vice President of Innovation PatientsLikeMe, UK Discovery: Workshop for Senior Jazz Panchoo Global Strategy Head, VP, Digital Platforms Executives Ascensia Diabetes Care, Switzerland This Event is Certified for Continuing Professional Development with more than 30 presentations
    [Show full text]
  • Read Our New Annual Report
    The seeds of a concept. The roots of an idea. The potential of a world free of age-related disease. Photo: Sherry Loeser Photography SENS Research Foundation Board of Directors Barbara Logan, Chair Bill Liao, Secretary Kevin Perrott, Treasurer Michael Boocher Jonathan Cain Kevin Dewalt Michael Kope Jim O’Neill Frank Schüler Sherry Loeser Photography 2 Contents CEO Letter (Jim O’Neill) 4 Finances 5 Donors 6 - 7 Fundraising & Conferences 8 - 9 Around the World with Aubrey de Grey 10 Outreach 11 Founding CEO Tribute & Underdog Pharmaceuticals 12 - 13 Investments 14 Welcome New Team Members 15 Education 16 - 17 Publications & Research Advisory Board 18 Research Summaries 19 - 22 Ways to Donate 23 The SRF Team Front row: Anne Corwin (Engineer/Editor), Amutha Boominathan (MitoSENS Group Lead), Alexandra Stolzing (VP of Research), Aubrey de Grey (Chief Science Officer), Jim O’Neill (CEO), Bhavna Dixit (Research Associate). Center row: Caitlin Lewis (Research Associate), Lisa Fabiny-Kiser (VP of Operations), Gary Abramson (Graphics), Maria Entraigues-Abramson (Global Outreach Coordinator), Jessica Lubke (Administrative Assistant). Back row: Tesfahun Dessale Admasu (Research Fellow), Amit Sharma (ImmunoSENS Group Lead), Michael Rae (Science Writer), Kelly Protzman (Executive Assistant). Not Pictured: Greg Chin (Director, SRF Education), Ben Zealley (Website/Research Assistant/ Deputy Editor) Photo: Sherry Loeser Photography, 2019 3 From the CEO At our 2013 conference at Queens College, Cambridge, I closed my talk by saying, “We should not rest until we make aging an absurdity.” We are now in a very different place. After a lot of patient explanation, publication of scientific results, conferences, and time, our community persuaded enough scientists of the feasibility of the damage repair approach to move SENS and SENS Research Foundation from the fringes of scientific respectability to the vanguard of a mainstream community of scientists developing medical therapies to tackle human aging.
    [Show full text]
  • How to Think and Act Rationally
    1 How to Be Rational: How to Think and Act Rationally David Robert [email protected] Abstract: This paper is divided into 4 sections. In Sections 1 and 2, I address (1) how to acquire rational belief attitudes and (2) how to make rational choices. Building on Sections 1 and 2, I then answer two of the most pressing questions of our time: (3) Should you be skeptical of climate change? (4) Should you invest in life-extension medical research? It has always appalled me that really bright scientists almost all work in the most competitive fields, the ones in which they are making the least difference. In other words, if they were hit by a truck, the same discovery would be made by somebody else about 10 minutes later. —Aubrey de Grey To make rational choices involves choosing courses of action that best serve one’s ends. As a good example, one’s chances of having a positive impact on the world are significantly greater if one focuses one’s efforts on solving the world’s biggest, most urgent problems than if one focuses one’s efforts on solving comparatively small, non-urgent problems that will not ultimately matter in the long run if the biggest, most urgent problems are left unsolved. Therefore, if one’s goal is to make a difference in the world, then it is simply not rational to focus one’s efforts on solving comparatively small, non-urgent problems. It is true that functioning societies do need people working on comparatively small day- to-day problems.
    [Show full text]
  • 321444 1 En Bookbackmatter 533..564
    Index 1 Abdominal aortic aneurysm, 123 10,000 Year Clock, 126 Abraham, 55, 92, 122 127.0.0.1, 100 Abrahamic religion, 53, 71, 73 Abundance, 483 2 Academy award, 80, 94 2001: A Space Odyssey, 154, 493 Academy of Philadelphia, 30 2004 Vital Progress Summit, 482 Accelerated Math, 385 2008 U.S. Presidential Election, 257 Access point, 306 2011 Egyptian revolution, 35 ACE. See artificial conversational entity 2011 State of the Union Address, 4 Acquired immune deficiency syndrome, 135, 2012 Black Hat security conference, 27 156 2012 U.S. Presidential Election, 257 Acxiom, 244 2014 Lok Sabha election, 256 Adam, 57, 121, 122 2016 Google I/O, 13, 155 Adams, Douglas, 95, 169 2016 State of the Union, 28 Adam Smith Institute, 493 2045 Initiative, 167 ADD. See Attention-Deficit Disorder 24 (TV Series), 66 Ad extension, 230 2M Companies, 118 Ad group, 219 Adiabatic quantum optimization, 170 3 Adichie, Chimamanda Ngozi, 21 3D bioprinting, 152 Adobe, 30 3M Cloud Library, 327 Adonis, 84 Adultery, 85, 89 4 Advanced Research Projects Agency Network, 401K, 57 38 42, 169 Advice to a Young Tradesman, 128 42-line Bible, 169 Adwaita, 131 AdWords campaign, 214 6 Affordable Care Act, 140 68th Street School, 358 Afghan Peace Volunteers, 22 Africa, 20 9 AGI. See Artificial General Intelligence 9/11 terrorist attacks, 69 Aging, 153 Aging disease, 118 A Aging process, 131 Aalborg University, 89 Agora (film), 65 Aaron Diamond AIDS Research Center, 135 Agriculture, 402 AbbVie, 118 Ahmad, Wasil, 66 ABC 20/20, 79 AI. See artificial intelligence © Springer Science+Business Media New York 2016 533 N.
    [Show full text]
  • Health Options Foreclosed: How the FDA Denies Americans the Benefits
    Health Options Foreclosed How the FDA Denies Americans the Benefits of Medical Research Richard Williams, Marc Joffe, and Ariel Slonim September 2016 MERCATUS WORKING PAPER Richard Williams, Marc Joffe, and Ariel Slonim. “Health Options Foreclosed: How the FDA Denies Americans the Benefits of Medical Research.” Mercatus Working Paper, Mercatus Center at George Mason University, Arlington, VA, September 2016. Abstract In recent decades, the Food and Drug Administration (FDA) has assumed increasing premarket authority for drugs and devices. Given how the FDA’s regulatory stance has inhibited breakthroughs in the development of medical products, it appears that the agency will stand in the way of emerging technologies such as nanotechnology, synthetic biology, nanorobotics, virally delivered telomerase, and cellular therapy. These new technologies represent not only the means to prevent and cure diseases, but also the key to helping people live longer and healthier lives. We conclude, therefore, that an incremental approach to reform—one that would keep the FDA as the sole arbiter of new medical technologies—is unlikely to work. Rather, we think that a regulatory system based on competitive market approval of drugs and devices is more likely to strike the appropriate benefit-risk balance, including that inherent in the compassionate use of experimental medical treatments. JEL codes: H11, I18, L65 Keywords: FDA, regulation, drugs, biotechnology, pharmaceuticals Author Affiliation and Contact Information Richard Williams Director for the Regulatory Studies Program Mercatus Center at George Mason University [email protected] Marc Joffe Principal Consultant Public Sector Credit Solutions [email protected] Ariel Slonim MA Fellow, Mercatus Center All studies in the Mercatus Working Paper series have followed a rigorous process of academic evaluation, including (except where otherwise noted) at least one double-blind peer review.
    [Show full text]
  • SENS Research Foundation Annual Report 2015
    S E N S R e s e a r c h F o u n d a t i o n has a unique mission: to ensure the development of cures which repair the underlying cellular and molecular damage of aging. This document, our 2 0 1 5 R e p o r t, demonstrates our commitment to delivering on the promise of that mission, and to meeting the challenges facing the rapidly emerging rejuvenation biotechnology field. Our research program delivers key proof-of-concept results. Our education program prepares the first generation of rejuvenation biotechnology professionals. Our outreach program widens and connects our communi. Our Rejuvenation Biotechnology conferences unite stakeholders from academic, industrial, political, regulatory and financial institutions. Together, we are transforming the way the world researches and treats age-related disease. i n t r o d u c t i o n 2 l e t t e r f r o m t h e C E O 3 c o m m u n i t y 4 o u t r e a c h 6 e d u c a t i o n 8 r e s e a r c h 1 0 f i n a n c e s 1 4 r e s e a r c h : p r o j e c t b y p r o j e c t 1 5 s u p p o r t i n g t h e f o u n d a t i o n 2 3 FOUNDATION BOARD OF LEADERSHIP DIRECTORS Mike Kope Barbara Logan Jonathan Cain Chief Executive Officer Board Chair Kevin Dewalt Kevin Perrott Dr.
    [Show full text]
  • El Transhumanisme Sota La Lupa Francesc Torralba, Coordinador Conferències Curs 2017-2018
    El Transhumanisme sota la lupa Francesc Torralba, coordinador Conferències curs 2017-2018 T E H E M O C R L U B O F BARCELONA Francesc Torralba Roselló és filòsof i teòleg. Neix a Barcelona el 15 de maig de 1967. Casat i pare de 5 fills. Doctor en Filosofia per la Universitat de Barcelona (1992). Doctor en Teologia per la Facultat de Teologia de Catalunya (1997). Doctor en Pedagogia per la Universitat Ramon Llull (2018). Amplia estudis a les Universitats de Copenhaguen i Berlín. En l’actualitat és catedràtic acreditat a la Universitat Ramon Llull, i imparteix cursos i seminaris en altres universitats d’Espanya i d’Amèrica. Alterna la seva activitat docent amb l’ofici d’escriure, i divulgar el seu pensament. Francesc Torralba és un autor prolífic, amb més de 1.500 articles i 100 llibres publicats dels quals destaquem: "El sentit de la vida" (2008), Biblioteca Francesc Torralba dedicada a valors amb títols com "La Tendresa", "La Paciència" o "L'Amistat", (2008), "Inteligencia Espiritual" (2010), "Jesucrist 2.0" (2011), "El valor de tenir valors" (2012), "Un mar d'e- mocions" (2013), "Córrer per pensar i sentir" (2015), "Saber dir no" (2016) i "La vida secreta de la pregària" (2017). Part de la seva obra ha estat traduïda al castellà, l'a- lemany, el francès, l'italià, el portuguès, el romanès i l'anglès. ament. EL TRANSHUMANISME SOTA LA LUPA Conferències curs 2017-2018 Amb la col.laboració de: Disseny i impressió: Vanguard Gràfic, SA ÍNDEX Introducción, de Jaime Lanaspa . 5 ¿De què parlem quan parlem de transhumanisme?, de Francesc Torralba .
    [Show full text]
  • Do Actuaries Believe in Longevity Deceleration? Edouard Debonneuil, Stéphane Loisel, Frédéric Planchet
    Do actuaries believe in longevity deceleration? Edouard Debonneuil, Stéphane Loisel, Frédéric Planchet To cite this version: Edouard Debonneuil, Stéphane Loisel, Frédéric Planchet. Do actuaries believe in longevity decelera- tion?. 2015. hal-01219270v2 HAL Id: hal-01219270 https://hal.archives-ouvertes.fr/hal-01219270v2 Preprint submitted on 5 Aug 2017 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. DO ACTUARIES BELIEVE IN LONGEVITY DECELERATION? Edouard Debonneuil Stéphane Loisel Frédéric Planchet* Univ Lyon - Université Claude Bernard Lyon 1, ISFA, Laboratoire SAF EA2429, F-69366, Lyon, France Prim’Act, 42 avenue de la Grande Armée, 75017 Paris, France ActuRx Version 2.0 du 05/08/2017 ABSTRACT As more and more people believe that significant life extensions may come soon, should commonly used future mortality assumptions be considered prudent? We find here that commonly used actuarial tables for annuitants – as well as the Lee-Carter model – do not extrapolate life expectancy at the same rate for future years as for past years; instead they produce some longevity deceleration. This is typically because their mortality improvements decrease after a certain age, and those age-specific improvements are constant over time.
    [Show full text]
  • SENS Research Foundation Annual Report 2014
    sens research foundation foundation report august 2014 mission 2 leer from the CEO 3 outreach 4 research 8 education 14 finances 16 research: project by project 18 FOUNDATION BOARD OF LEADERSHIP DIRECTORS Mike Kope Barbara Logan Jonathan Cain Chief Executive Officer Board Chair Kevin Dewalt Kevin Perrott Aubrey de Grey Treasurer James O’Neill Chief Science Officer Bill Liao Mike Kope Secretary © 2014, SENS Research Foundation a: 110 Pioneer Way, Suite J / Mountain View, CA 94041 / USA p: 650.336.1780 f: 650.336.1781 www.sens.org All rights reserved. No part of this material may be reproduced without specific permission from SENS Research Foundation. SENS Research Foundation’s federal employer ID number is 94-3473864. Because SENS Research Foundation is a 501(c)(3) non-profit, your donation may be tax deductible. transforming the way the world researches and treats age-related disease We fund research at institutions around the world, and at our own Moun- tain View facility. Our research is integrated with wide-ranging outreach and education programs. Our goal is to see the emergence of an industry that will cure the diseases of aging, an industry based around what we call rejuvenation biotechnology. Many things go wrong with aging bodies, but at the root of them all is the burden of decades of unrepaired damage to the cellular and molecular structures that make up the functional units of our tissues. Faced with the diseases and disabilities caused by this damage, today’s medicine is too often reduced to crisis management in the emergency room, painfully harsh treatments for diseases such as cancer, or best efforts at palliative care.
    [Show full text]
  • Longevidad Y Envejecimiento En El Tercer Milenio: Nuevas Perspectivas
    LONGEVIDAD Y ENVEJECIMIENTO EN EL TERCER MILENIO: NUEVAS PERSPECTIVAS JOSÉ MIGUEL RODRÍGUEZ-PARDO DEL CASTILLO ANTONIO LÓPEZ FARRÉ LONGEVIDAD Y ENVEJECIMIENTO EN EL TERCER MILENIO: NUEVAS PERSPECTIVAS José Miguel Rodríguez-Pardo del Castillo Profesor del Máster en Ciencias Actuariales y Financieras Universidad Carlos III, Madrid Antonio López Farré Profesor de la Facultad de Medicina. Departamento de Medicina. Codirector del Aula AINTEC Universidad Complutense de Madrid Fundación MAPFRE no se hace responsable del contenido de esta obra, ni el hecho de publicarla implica conformidad o identificación con las opiniones vertidas en ella. Reservados todos los derechos. Está prohibido reproducir o transmitir esta publicación, total o parcialmente, por cualquier medio, sin la autorización expresa de los editores, bajo las sanciones establecidas en las leyes. Imágenes de cubierta e interiores: ThinkStock Maquetación e impresión: Edipack Gráfico © De los textos: sus autores © De esta edición: 2017, Fundación MAPFRE Paseo de Recoletos, 23 28004 Madrid www.fundacionmapfre.org ISBN: 978-84-9844-648-7 Depósito Legal: M-18221-2017 «Los hombres son como los vinos: la edad agria los malos y mejora los buenos». Marco Tulio Cicerón «Solo la alegría es señal de salud y longevidad». Santiago Ramón y Cajal «No anheléis la inmortalidad, pero agotad el límite de lo posible». Píndaro Agradecimiento: Los autores quieren agradecer a Begoña Larrea Cruz su excelente y dedicada labor en la edición de esta obra, sin cuya ayuda no hubiera sido nunca finalizada. PRESENTACIÓN Desde 1975 Fundación MAPFRE desarrolla actividades de interés general para la sociedad en distintos ámbitos profesionales y culturales, así como ac- ciones destinadas a la mejora de las condiciones económicas y sociales de las personas y de los sectores menos favorecidos de la sociedad.
    [Show full text]
  • Return of Organization Exempt from Income Tax OMB No
    Extended to November 15, 2018 Return of Organization Exempt From Income Tax OMB No. 1545-0047 Form 990 Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except private foundations) 2017 Department of the Treasury | Do not enter social security numbers on this form as it may be made public. Open to Public Internal Revenue Service | Go to www.irs.gov/Form990 for instructions and the latest information. Inspection A For the 2017 calendar year, or tax year beginning and ending B Check if C Name of organization D Employer identification number applicable: Address change SENS Foundation Inc. Name change Doing business as Sens Research Foundation, Inc. 94-3473864 Initial return Number and street (or P.O. box if mail is not delivered to street address) Room/suite E Telephone number Final return/ 110 Pioneer Way J (650) 336-1780 termin- ated City or town, state or province, country, and ZIP or foreign postal code G Gross receipts $ 8,057,919. Amended return Mountain View, CA 94041 H(a) Is this a group return Applica- tion F Name and address of principal officer: Michael Kope for subordinates? ~~ Yes X No pending same as C above H(b) Are all subordinates included? Yes No I Tax-exempt status: X 501(c)(3) 501(c) ( )§ (insert no.) 4947(a)(1) or 527 If "No," attach a list. (see instructions) J Website: | WWW.SENS.ORG H(c) Group exemption number | K Form of organization: X Corporation Trust Association Other | L Year of formation: 2009 M State of legal domicile: CA Part I Summary 1 Briefly describe the organization's mission or most significant activities: Develop, promote and ensure widespread access to rejuvenation biotechnologies.
    [Show full text]